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Conclusions: In the contemporary era, the presence of baseline LV dysfunction in
patients undergoing primary PCI is a powerful predictor of early and late mortality,
regardless of the extent of coronary artery disease.
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Background: Previous studies have reported varying outcomes in pts with ACS and
non-obstructive CAD. Whether non-obstructive CAD confers the same prognosis in pts
with unstable angina (UA) compared to those with NSTEMI is unknown.
Methods: Of 6,921 pts with ACS undergoing an early invasive strategy in whom
quantitative angiography of the entire coronary artery tree was performed in the ACUITY
trial, those with a maximum stenosis of 50 % in all coronary arteries were defined as
non-obstructive CAD. Baseline features and outcomes through 1-year follow-up in such
pts treated without revascularization were examined according to whether they presented
with UA (CKMB or troponin ) or NSTEMI (CKMB or troponin 	).
Results: Non-obstructive CAD was present in 955 pts (14.4%) treated conservatively;
603 (63.1%) had UA whereas 352 (26.9%) had NSTEMI. Compared to pts with UA, pts
with NSTEMI were paradoxically less likely to require insulin; have hypertension or
hyperlipidemia; have had a prior MI or a previous PTCA; or present with ST-segment
deviation  1mm. Pts with NSTEMI were more likely to present at low to intermediate
TIMI risk. A similar percentage of pts with NSTEMI and UA received aspirin and/or a
thienopyridine on discharge. Pts with NSTEMI were more than twice as likely to die or
have an MI by 1 year than pts with UA, whereas unplanned revascularization was more
common in those with UA (Table).
Conclusions: Among ACS pts with non-obstructive CAD treated conservatively in the
ACUITY trial, despite having fewer cardiovascular risk factors at baseline, similar use of
anti-platelet therapies and requiring fewer revascularization procedures, pts with NSTEMI
were more than twice as likely as those with UA to die or have a MI by 1 year. Novel
approaches are required for pts with NSTEMI and non-obstructive CAD.
One-year clinical outcomes in patients with NSTEMI vs. UA
Outcome NSTEMI UA HR [95% CI] P-value
All-cause death 3.2 (11) 1.8 (10) 1.89 (0.80 - 4.54) 0.14
Myocardial infarction 1.5 (5) 0.2 (1) 8.33 (1.01 - 100.0) 0.02
Death or myocardial
infarction
4.7 (16) 2.0 (11) 2.50 (1.16 - 5.56) 0.01
Unplanned
revascularization
0.3 (1) 1.9 (11) 0.16 (0.02 - 1.20) 0.04
MACE 5.0 (17) 3.5 (20) 1.47 (0.77 - 2.78) 0.25
Value estimates are % (n) determined by Kaplan-Meier methods.
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Background: Among patients with acute ST-segment elevation myocardial infarction-
(STEMI), early generation drug-eluting stents(DES) improve efficacy but not safety
compared with bare metal stents(BMS). Newer generation DES eluting everolimus(EES)
and biolimus A9(BES) have been shown to improve clinical outcomes compared with
early generation DES. However, it remains to be determined whether the benefits of
newer over early generation DES translate into improved safety compared with BMS
among appropriately powered population with STEMI.
Methods: Individual patient data of 2665 patients with STEMI enrolled into two large
scale randomized clinical trials comparing newer generation DES with BMS were pooled:
EXAMINATION randomly assigned 1504 patients to treatment with EES or BMS, and
COMFORTABLE AMI randomly assigned 1161 patients to treatment with BES or BMS.
Random effect models were used to assess differences in clinical outcomes between newer
generation DES and BMS for the pre-specified device-oriented composite of cardiac
death, target-vessel reinfarction and target-lesion revascularization and the patient-
oriented composite of death, reinfarction and any revascularization at one year.
Results: Newer generation DES substantially reduced the risk of the primary device-
oriented composite outcome compared with BMS at one year(RR 0.58, CI 95% 0.43 -
0.79, p 0.0004). Similarly, the risk of the primary patient-oriented composite outcome
was lower with newer generation DES than BMS(RR 0.78, 95% CI 0.63 to 0.96, p0.02).
Differences in favor of newer generation DES were driven by both, a lower risk of repeat
revascularization of the target lesion(RR 0.33, 95% CI 0.20–0.52, p0.0001) and a lower
risk of target-vessel reinfarction(RR 0.36, 95% CI 0.14-0.92, p0.03). Newer generation
DES reduced the risk of acute(RR 0.38, 95% CI 0.17-0.85, p0.02) and overall(within
one year) definite stent thrombosis(RR 0.35, 95% CI 0.16 – 0.75, p0.006) compared
with BMS.
Conclusions: Among patients with STEMI, newer generation DES improved safety and
efficacy compared with BMS throughout one year. It remains to be determined whether
these differences in favor of newer generation DES remain sustained during long-term
follow-up.
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Background: The purpose of this study was to determine safety and efficiency of
one-stage PCI of left main coronary artery (LMCA) and infarct-related left anterior
descending (LAD) or left circumflex (LCX) arteries in ST-elevation myocardial infarction
(STEMI). Even though STEMI guidelines recommend to limit the procedure to infarct-
related artery there are cases when it’s impossible to complete the PCI of the infarct-
related LAD or LCX without affecting LMCA. Appropriateness of one-phase PCI in such
cases needs to be investigated.
Methods: 281 PCI of LMCA were performed during the last 5 years. There were 57
stable and 224 ACS patients among them. LMCA lesion as the reason of ACS was in 19
patients, they were not included into the study. In other 205 cases LAD or LCX were
symptom-related accompanying significant LMCA lesions. The ACS subgroup (205
patients) contained 108 non-ST ACS patients and 97 STEMI patients. These 97 STEMI
patients with LMCA stenosis and infarct-related LAD or LCX were of major interest and
were followed up for 4 years.
Results: LAD was infarct-related in 65% of cases, LCX - in 35%. 7 patients were
admitted with cardiogenic shock. Concomitant RCA lesion was in 60% of cases. Most
procedures were performed using transradial approach (81%), IABP was used in 41% of
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patients, IVUS was made in 27% of cases. All patients were treated with drug eluting
stents (DES). 4 patients died during the procedure, 2 more patients died during
hospitalization, so hospital mortality was 6.2%. There were no repeated myocardial
infarctions or target vessel revascularizations during hospitalization. Recurrent angina
symptoms due to untreated lesions occurred in 38 patients (39%). 10 patients (10.3%) died
during the follow up period. Therefore 4 year mortality was 16.5%. Target lesion
revascularization was performed in 11 patients (11%). Among them there were 3 cases of
repeated PCI of LMCA. Myocardial infarction occurred in 8 patients. PCI of untreated
lesions was performed in 14 patients (14%). MACCE-free survival was 55.1%.
Conclusions: PCI of LMCA and infarct-related LAD or LCX arteries in STEMI patients
is effective and safe. Further trials with longer follow up periods are required.
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Background: Cigarette smoking was associated with higher rates of myocardial
infarction (MI) and death from coronary artery disease. However, despite the increased
prevalence of ischemic heart disease in current smokers, prior studies showed that
smokers undergoing primary percutaneous coronary intervention (PCI) had lower
mortality rate than nonsmokers. The impact of cigarette smoking in patients with acute MI
after drug-eluting stent (DES) implantation has not been examined.
Methods: From databases of our hospital, 1242 patients who confirmed acute MI and
underwent successful PCI with DES were consecutively enrolled. Cardiac death, non-fatal
MI, target lesion revascularization at 12 months after procedure were assessed.
Results: Five hundred fifty patients (44.3%) were current smokers. In comparison to
nonsmokers, current smokers were younger, more often men, less frequently had diabetes,
hypertension and hyperlipidemia, showed lower serum creatinine level, and frequent
medication of ACE inhibitor. Cardiac mortality at 12 months was significantly lower in
current smokers (1.1% vs. 3.0%, p0.019). However, current smoking status was no
longer protective from cardiac mortality in multivariate analysis (hazard ratio 0.395, 95%
CI 0.1301.195, p0.100).
Conclusions: The current smoker showed increased survival than nonsmoker. However,
its result entirely explained by difference in baseline risk factors.
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Background: The aim of this study was to identify simple electrocardiographic (ECG)
parameters given automatically in a contemporary ECG machine predicting major adverse
cardiac events (MACE) after acute myocardial infarction (AMI).
Methods: Between November 2005 and January 2008, 489 post-MI hospital survivors
who had an ECG 3 to 7 days after the attack were included. Philips Trace Master Vue
ECG management system was used to obtain ECG parameters. The MACEs were defined
as death, non-fatal MI, and heart failure readmission. Mean follow-up duration was 396.8
 140.7 (41285 days) days.
Results: Complete follow-up data were available in 468 (95.7%) patients. During the
follow-up, 57 (12.2%) MACEs occurred. In univariate analysis, patients with MACE had
higher time-voltage QRS area, longer Q wave and ST duration, pathologic Q wave in I,
aVL lead, lateral ST depression and T wave inversion in V1-4 among ECG variables. In
the Cox proportional hazard model, time voltage QRS area (hazard ratio [HR] 0.017, 95%
confidence interval [CI] 1.008 to 1.081, p  0.017) and ST duration (HR 1.013, 95% CI
1.006 to 1.020, p 0.001) were independent predictors of MACEs among ECG variables
after adjustment for confounding variables. In receiver-operator characteristic curve, the
area under the curve (AUC) of QRS area for predicting MACEs was 0.696 (sensitivity
77.2% and specificity 56.2%), and optimum cut-off value was 11.55 Ashman units (AU).
The AUC of ST duration was 0.635 (sensitivity 57.9% and specificity 65.9%), and
optimum cut-off value was 170 ms. Kaplan-Meier survival curve showed that patients
with QRS area of 11.55 AU or more (19.6% versus 5.3%; log-rank p  0.001) had
significantly higher MACEs compared with patients with QRS area 11.55 AU. Patient
with ST duration of 170 ms or more (19.1% versus 8.1%; log-rank p  0.001) had
significantly higher MACEs compared with patients with ST duration  170 ms.
Conclusions: This study suggests that time-voltage QRS area measurements and ST
duration derived from a standard digitally acquired 12-lead ECG using commercially
available equipment could provide prognostic value in hospital survivors after AMI.
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Background: The in-hospital delay between admission and successful coronary reper-
fusion (“door- to- balloon” time interval, DTB) in patients with a diagnosis of STEMI is
a predictor of mortality. Reducing the DTB time below 90 minutes- as suggested in
current guidelines- represents a major challenge for most hospitals as recent registry data
report. Simple strategies to reduce the DTB time, therefore, are crucial.
Methods: We aimed to evaluate the impact of a simple strategy to the reduce DTB time
in patients with STEMI by bypassing the emergency room. To facilitate this aim, we
implemented a protocol with “standard- operating procedures” (SOP) defining two
different clinical scenarios (scenario A: patient is stable and can be directly transferred to
the cath- lab, scenario B: patient is unstable or cath- lab is occupied). Medical staff in the
emergency department, the intensive care unit and the cath- lab were trained accordingly.
56 patients with STEMI, admitted to the hospital from September 2009 to Januar 2010,
were enrolled in this study and served as the control group (“pre-protocol”). After
implementing the SOP, 58 consecutive patients with acute STEMI were enrolled between
September 2010 to March 2011 (“post-protocol”).
Results: Baseline characteristics did not differ between both groups regarding age,
gender, body mass index or cardiovascular risk factors. The “symptom-to-door” time
interval did not differ between patients before and after establishing the protocol (267 
332 versus 276  272 min; p0,884). The “door-to balloon” time, however, was
significantly reduced as a result of establishing the protocol (89  49 vs. 70  34;
p0,019).
Conclusions: Defining simple standards (SOP) for the intra- hospital workflow in
patients with STEMI and respective training of staff members lead to a significant
reduction in DTB intervals. Further studies will have to show whether these measures
translate into a significant reduction in mortality.
TCT-486
Relationship Between White Blood Cell Count and Final Infarct Size in
Patients with ST-Segment Elevation Acute Myocardial Infarction Undergoing
Primary Percutaneous Coronary Intervention: Analysis from the INFUSE-
AMI Trial
Tullio Palmerini1, Sorin Brener2, Jan-Henk Dambrink3, Martin Fahy4,
C. Michael Gibson5, Jacek Godlewski6, Akiko Maehara7, Andrzej Ochala8,
Helen Parise9, Gregg Stone10, Bernhard Witzenbichler11
1Policlinico S.Orsola, Bologna, Italy, 2New York Methodist Hospital, Brooklyn,
NY, 3Isala klinieken, Zwolle, Netherlands, 4Cardiovascular Research Foundation,
New York, NY, 5Beth Israel Deaconess Med Ctr - Harvard Medical School,
Boston, USA, 6Jagiellonian University School of Medicine, Krakow, Poland,
7Cardiovascular Reserach Foundation, New York, NY, 8Assistant Professor,
Katowice, Poland, 9Cardiovascular Research Foundation, New York, NY,
10Columbia University Medical Center and the Cardiovascular Research
Foundation, New York, NY, 11Charité Campus Benjamin Franklin, Berlin,
Germany
Background: Although elevated white blood cell count (WBCc) is associated with an
increased risk of mortality in patients with ST-segment elevation myocardial infarction
(STEMI) undergoing primary percutaneous coronary intervention (PCI), the mechanisms
underlying this association are unknown. We sought to investigate whether elevated
WBCc is associated with increased infarct size measured with cardiac magnetic resonance
imaging (cMRI) 30 days after primary PCI in the INFUSE AMI trial.
Methods: INFUSE AMI was a 2x2 factorial design trial in which patients with STEMI
and proximal or mid left anterior descending (LAD) coronary artery occlusion receiving
bivalirudin anticoagulation were randomized to bolus intracoronary abciximab via the
ClearWay RX catheter vs no abciximab and to manual aspiration with the Export catheter
vs no aspiration. WBCc at hospital admission was available in 323 of 353 randomized
patients who had evaluable infarct size with cMRI at 30 days. Patients were stratified
according to tertiles of WBCc (tertile I9,700/l; 9,700/ltertile II13,200/l; tertile
III13,200/l).
Results: At 30 days, a significant stepwise increase in infarct size (percentage of total left
ventricular mass) was apparent across tertiles of WBCc (median [IQR] for tertiles I vs. II
vs. III  11.2% [3.8%-19.6%] vs. 17.5% [0.5%-22.9%] vs. 19.1% [13.7-26.0] respec-
tively; p0.0001). Absolute infarct mass in grams (13.7 [4.2-29.7] vs. 21.4 [13.9-32.0] vs.
25.6 [17.6-36.1]; p0.0001) and abnormal wall motion score (5.0 [0.0-10.0] vs. 8.0
[2.0-10.0] vs. 8.0 [4.0-11.0]; p0.0001) were also significantly increased across tertiles of
WBC. By multivariable linear regression analysis WBC was an independent predictor of
infarct size (P0.0001) along with intracoronary abciximab randomization, age, time
from symptom onset to first device, proximal LAD location, and baseline TIMI flow 0/1.
Conclusions: In patients with anterior STEMI undergoing primary PCI, an elevated
admission WBCc is a powerful independent predictor of increased infarct size measured
with cMRI 30 days after primary PCI, and should be considered in risk models along with
more traditional correlates such as myocardium at risk, TIMI flow and time to reperfusion.
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